Pharmacogenomics Market Demands and Gross Margin 2026

Press Release

Pharmacogenomics is an essential research area for development of medication for pain, cancer, psychotropic, and cardiovascular disease. The success of this medication is possible through the use of innovative technologies that help define the dosage setting for subsets of the population and an individual’s response to a specific drug. The success of the precision medicine is possible through the application of pharmacogenomics that uses information about a person’s genes, enzyme activities, cellular environment, and proteins to diagnose and treat diseases. Rapid advancements in groups of specialized molecular diagnostic tests is contributing to the improvement for assessment of real-time treatment of diseases.

Get Sample Copy at:

Market Dynamics

Major factors that propel the market are increasing demand for personalized drugs, increasing prevalence of several non-infectious and infectious diseases, rising utilization of these technology for effective treatment therapeutics, and growing awareness about benefits associated with pharmacogenomics. Continuous collaboration among pharmacogenomics manufacturers for various applications in clinical and translational research is also expected to drive growth of the market across regions. In 2016, Merck & Co. Inc., collaborated with Biocartis, an innovative molecular diagnostic company to develop and commercialize a new liquid biopsy technology for RAS biomarker testing. This can enable more access to the test for number of metastatic colorectal cancer patients. Furthermore, use of pharmacogenomics to perform diagnostic assays in the field of determining individual’s susceptibility to certain diseases, toxicology, biochemical genetics, and drug safety are also expected to lead to rapid growth of the market for pharmacogenomics over the forecast period.

Increasing demand for various techniques to pinpointing diagnoses down to the subtype of chronic conditions will drive the pharmacogenomics market

Increasing number of research studies pertaining to sequencing, especially next generation sequencing, are expected to increase demand for pharmacogenomics tests. Meteoric progress in the aspects of NGS technology, platform, and data analysis solutions is propelling widespread, as it shows valid results for problematic areas that have long plagued the drug development industry.

 Increasing prevalence of several infectious and non-infectious diseases is also one of the major factors boosting the demand for regulated next-generation sequencing-based clinical trial assays and companion diagnostics. According to U.S. Food and Drug Administration (FDA) statistics, over 100,000 people in the U.S. die each year from injurious responses to drugs that were correctly prescribed by a physician. Additionally, over 2.2 million people endure acute, though not fatal, side effects. Worldwide, BioWorld estimates those figures increase to 200,000 deaths and over 4.5 million people suffering serious side effects.

Pharmacogenomics tests are expected to predict susceptibility to maladies as well as create therapeutics tailored to an individual’s specific genetic profile. This in turn, is expected to increase market growth. However, unavailability of proper diagnostic testing due to lack of trained personnel, high costs associated with tests, dearth of laboratory facility, and lack of standardization and validation of the test procedures hampers the development of the personalized medicine.

Technological advancements leading to new product launch is a prominent factor fueling market growth

Today, screening of known polymorphic drug metabolism enzymes and transporters (DMET) is rapidly becoming routine practice in clinical research. So manufacturers are currently focusing on various approaches to pharmacogenomics analysis to provide rapid and cost-effective solutions for both the screening of known polymorphisms and discovery of novel variants. Few of the advanced technologies already been commercialized like Illumina HiSeq-2000 and HiScan, Roche 454 GSFLX Titanium and the Applied Biosystems SOLiD Analyzer 5500xl. Besides, the combination of goldstandard Applied Biosystems TaqMan Assays with the high-throughput Applied Biosystems Open Array manufactured by Thermo Fisher Scientific Inc., enables analysis of common variants, typically in under four hours with the flexibility to modify array content.

Buy Now This Report:

Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc.

This post was originally published on Trading Herald

RSS news